SCHEMBL5043418

SCHEMBL5043418

CC1(C)COc2ccc(C#Cc3ccc(OCC4CO4)cc3)cc2OC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACACB O00763 3/20 0.47
ALDH1A1 P00352 4/20 0.44
TP53 P04637 3/20 0.44
TSHR P16473 3/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
HIF1A Q16665 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
PPARG P37231 1/20 0.44
TDP1 Q9NUW8 1/20 0.42
CYP3A4 P08684 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PKM P14618 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
FFAR1 O14842 6/20 0.37
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046828 0.86 ACACB (0.48) ACACBTDP1
SCHEMBL5043403 0.83 ACACB (0.52) ACACBALDH1A1TP53MAPTMEN1
SCHEMBL5048237 0.82 ACACB (0.49) ACACBMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5043671 0.81 ACACB (0.50) ACACBMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5043437 0.80 ACACB (0.51) ACACBALDH1A1TP53MAPTHPGD
SCHEMBL5043428 0.80 ACACB (0.49) ACACBALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL14062954 0.78 TDP1 (0.66) ACACBALDH1A1TP53TSHRMAPT
SCHEMBL14063103 0.78 TDP1 (0.66) ACACBALDH1A1TP53TSHRMAPT
SCHEMBL5046911 0.75 ACACB (0.53) ACACBALDH1A1HPGDTDP1CYP3A4
SCHEMBL5046845 0.74 ACACB (0.56) ACACBMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US claimed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP claimed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US claimed
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP disclosed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113374-A1 Benzodioxepine derivatives BBOX1, ACOX1, ACOX3 ACACB 5/4885ALDH1A1 361/4885TP53 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.